Literature DB >> 18224451

Genistein induces G2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells.

Zhong Li1, Jing Li, Baoqing Mo, Chunyan Hu, Huaqing Liu, Hong Qi, Xinru Wang, Jida Xu.   

Abstract

Genistein is an isoflavonoid present in soybeans that exhibits anti-carcinogenic effect. Several studies have shown that genistein can trigger G2/M cell cycle arrest and inhibit cell growth in human breast cancer cells. In the present study, we assessed the role of MEK-ERK cascade in regulation of genistein-mediated G2/M cell cycle arrest in the hormone-independent cell line MDA-MB-231. Flow cytometric analysis showed that treatment of MDA-MB-231 cells with genistein induced a concentration-dependent accumulation of cells in the G2/M phase of the cell cycle, with a parallel depletion of the percentage of cells in G0/G1. Genistein-mediated G2/M arrest was associated with a decrease in the protein levels of Cdk1, cyclinB1, and Cdc25C as determined by Western blot analysis. Genistein induced a slow and stable activation of phosphorylated ERK1/2 in a concentration- and time-dependent manner in MDA-MB-231 cells. MEK1/2-specific inhibitor PD98059 blocked genistein-induced activation of ERK1/2 and markedly attenuated genistein-induced G2/M arrest. Furthermore, genistein induced the expression of Ras and Raf-1 protein. Genistein also up-regulated steady-state levels of both c-Jun and c-Fos. PD98059 did not depress genistein-induced up-regulation of Ras and Raf-1 protein. However, it markedly blocked genistein-induced up-regulation of c-Jun and c-Fos. These results suggest that the Ras/MAPK/AP-1 signal pathway may be involved in genistein-induced G2/M cell cycle arrest in MDA-MB-231 breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18224451     DOI: 10.1007/s10565-008-9054-1

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  23 in total

1.  Acoustophoretic synchronization of mammalian cells in microchannels.

Authors:  Patrick Thévoz; Jonathan D Adams; Herbert Shea; Henrik Bruus; H Tom Soh
Journal:  Anal Chem       Date:  2010-04-01       Impact factor: 6.986

2.  Genistein protects against biomarkers of delayed lung sequelae in mice surviving high-dose total body irradiation.

Authors:  Regina M Day; Michal Barshishat-Kupper; Steven R Mog; Elizabeth A McCart; P G S Prasanna; Thomas A Davis; Michael R Landauer
Journal:  J Radiat Res       Date:  2008-04-23       Impact factor: 2.724

Review 3.  Cancer prevention with promising natural products: mechanisms of action and molecular targets.

Authors:  Poyil Pratheeshkumar; Chakkenchath Sreekala; Zhuo Zhang; Amit Budhraja; Songze Ding; Young-Ok Son; Xin Wang; Andrew Hitron; Kim Hyun-Jung; Lei Wang; Jeong-Chae Lee; Xianglin Shi
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

Review 4.  Genistein as a regulator of signaling pathways and microRNAs in different types of cancers.

Authors:  Zeeshan Javed; Khushbukhat Khan; Jesús Herrera-Bravo; Sajid Naeem; Muhammad Javed Iqbal; Haleema Sadia; Qamar Raza Qadri; Shahid Raza; Asma Irshad; Ali Akbar; Željko Reiner; Ahmed Al-Harrasi; Ahmed Al-Rawahi; Dinara Satmbekova; Monica Butnariu; Iulia Cristina Bagiu; Radu Vasile Bagiu; Javad Sharifi-Rad
Journal:  Cancer Cell Int       Date:  2021-07-21       Impact factor: 6.429

5.  Does consuming isoflavones reduce or increase breast cancer risk?

Authors:  Maria Bondesson; Jan-Ake Gustafsson
Journal:  Genome Med       Date:  2010-12-21       Impact factor: 11.117

6.  Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.

Authors:  Klaus H Baumann; Elmar Klusmeier; Isabel Eggemann; Silke Reinartz; Achim Almeroth; Mathias Kalder; Uwe Wagner
Journal:  Breast Cancer (Auckl)       Date:  2009-04-07

7.  Recombinant immunotoxin anti-c-Met/PE38KDEL inhibits proliferation and promotes apoptosis of gastric cancer cells.

Authors:  Xu Wei; Zhu Xiao Juan; Feng Xiao Min; Cai Nan; Zhang Xiu Hua; Feng Zheng Qing; Liu Zheng
Journal:  J Exp Clin Cancer Res       Date:  2011-07-07

8.  CCL21/CCR7 promotes G2/M phase progression via the ERK pathway in human non-small cell lung cancer cells.

Authors:  Ying Xu; Lifeng Liu; Xueshan Qiu; Lili Jiang; Bo Huang; Haiying Li; Zixuan Li; Wenting Luo; Enhua Wang
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

9.  CCL21/CCR7 prevents apoptosis via the ERK pathway in human non-small cell lung cancer cells.

Authors:  Ying Xu; Lifeng Liu; Xueshan Qiu; Zihui Liu; Haiying Li; Zixuan Li; Wenting Luo; Enhua Wang
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

Review 10.  Zinc and cancer: implications for LIV-1 in breast cancer.

Authors:  Bruce J Grattan; Hedley C Freake
Journal:  Nutrients       Date:  2012-07-04       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.